ProKidney Announces Pricing of Its Upsized $130 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.